

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 June 2023 (29.06.2023)



(10) International Publication Number
WO 2023/122588 A2

- (51) **International Patent Classification:**
A61K 47/68 (2017.01) *C07D 257/02* (2006.01)
- (21) **International Application Number:**
PCT/US2022/082021
- (22) **International Filing Date:**
20 December 2022 (20.12.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/291,910 20 December 2021 (20.12.2021) US
- (71) **Applicants:** **FUSION PHARMACEUTICALS INC.** [CA/CA]; 270 Longwood Road South, Hamilton, Ontario L8P 0A6 (CA). **ASTRAZENECA UK LIMITED** [GB/GB]; 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB).
- (72) **Inventors:** **AGHEVLIAN, Sadaf**; 15 Legion Road, Etobicoke, Ontario M8V0A9 (CA). **GRINSHTEIN, Natalie**; 3630 212th Pl. SE, Bothell, Washington 98021 (US). **DUFFY, Ian, R.**; 268 Ellen Davidson Drive, Oakville, Ontario L6M 0V2 (CA). **KOSTELNIK, Thomas, I.**; 199 Catharine Street N, Hamilton, Ontario L8L 4S4 (CA). **BUCHANAN, Andrew, Grier**; Milstein Building, Granta Park, Cambridge CB21 6GH (GB). **MAZOR, Yariv**; One MedImmune Way, Gaithersburg, Maryland 20878 (US). **KASTURIRANGAN, Srinath**; One MedImmune Way, Gaithersburg, Maryland 20878 (US). **DU, Qun**; One MedImmune Way, Gaithersburg, Maryland 20878 (US). **YANG, Chunning**; One MedImmune Way, Gaithersburg, Maryland 20878 (US). **COMER, Frank, Irvine**; One MedImmune Way, Gaithersburg, Maryland 20878 (US).
- (74) **Agent:** **JACOBSTEIN, Jeffrey, M.** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, D.C. 20001-4413 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) **Title:** EGFR-CMET-TARGETED COMPOUNDS AND USES THEREOF

(57) **Abstract:** Compounds, e.g., radioimmunoconjugates, including a chelating moiety or a metal complex thereof, a linker, and an antibody or antigen-binding fragment thereof targeting both EGFR and cMET. Pharmaceutical compositions of such compounds and methods of treatment for conditions, e.g., cancer, using such compounds or pharmaceutical compositions.




FIG. 1A

WO 2023/122588 A2